Table 3 Changes in markers of bone metabolism and hip BMD during the observation period
From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study
Baseline | End of study | P* | |
|---|---|---|---|
TRACP-5b (mU/dL) | 785.3 ± 385.8 | 638.2 ± 423.4 | 0.03 |
BALP (μg/L) | 18.1 ± 11.4 | 17.4 ± 10.3 | 0.55 |
Hip BMD (g/cm2), n = 9 | 0.51 ± 0.10 | 0.47 ± 0.11 | 0.07 |